249 related articles for article (PubMed ID: 11939808)
1. Interferon alfa-2a in the treatment of Behçet disease: a randomized placebo-controlled and double-blind study.
Alpsoy E; Durusoy C; Yilmaz E; Ozgurel Y; Ermis O; Yazar S; Basaran E
Arch Dermatol; 2002 Apr; 138(4):467-71. PubMed ID: 11939808
[TBL] [Abstract][Full Text] [Related]
2. Treatment of Adamantiades-Behçet disease with systemic interferon alfa.
Zouboulis CC; Orfanos CE
Arch Dermatol; 1998 Aug; 134(8):1010-6. PubMed ID: 9722733
[TBL] [Abstract][Full Text] [Related]
3. Long-term efficacy and safety of low-dose and dose-escalating interferon alfa-2a therapy in refractory Behçet uveitis.
Onal S; Kazokoglu H; Koc A; Akman M; Bavbek T; Direskeneli H; Yavuz S
Arch Ophthalmol; 2011 Mar; 129(3):288-94. PubMed ID: 21402983
[TBL] [Abstract][Full Text] [Related]
4. Interferon alfa-2a in the treatment of Behçet's disease.
Azizlerli G; Sarica R; Köse A; Ovül C; Kavala M; Kayabali M; Erkan F; Kural Z
Dermatology; 1996; 192(3):239-41. PubMed ID: 8726638
[TBL] [Abstract][Full Text] [Related]
5. Human recombinant interferon alfa-2a for the treatment of Behçet's disease with sight threatening posterior or panuveitis.
Kötter I; Zierhut M; Eckstein AK; Vonthein R; Ness T; Günaydin I; Grimbacher B; Blaschke S; Meyer-Riemann W; Peter HH; Stübiger N
Br J Ophthalmol; 2003 Apr; 87(4):423-31. PubMed ID: 12642304
[TBL] [Abstract][Full Text] [Related]
6. The use of sucralfate suspension in the treatment of oral and genital ulceration of Behçet disease: a randomized, placebo-controlled, double-blind study.
Alpsoy E; Er H; Durusoy C; Yilmaz E
Arch Dermatol; 1999 May; 135(5):529-32. PubMed ID: 10328192
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of interferon alfa-2a in severe and refractory uveitis associated with Behçet's disease.
Wechsler B; Bodaghi B; Huong DL; Fardeau C; Amoura Z; Cassoux N; Piette JC; LeHoang P
Ocul Immunol Inflamm; 2000 Dec; 8(4):293-301. PubMed ID: 11262659
[TBL] [Abstract][Full Text] [Related]
8. [Ocular involvement in Behçet's disease: first 5-year-results for visual development after treatment with interferon alfa-2a].
Deuter CM; Kötter I; Günaydin I; Zierhut M; Stübiger N
Ophthalmologe; 2004 Feb; 101(2):129-34. PubMed ID: 14991308
[TBL] [Abstract][Full Text] [Related]
9. Interferon alfa-2a is ineffective for patients with choroidal neovascularization secondary to age-related macular degeneration. Results of a prospective randomized placebo-controlled clinical trial. Pharmacological Therapy for Macular Degeneration Study Group.
Arch Ophthalmol; 1997 Jul; 115(7):865-72. PubMed ID: 9230826
[TBL] [Abstract][Full Text] [Related]
10. Thalidomide in the treatment of the mucocutaneous lesions of the Behçet syndrome. A randomized, double-blind, placebo-controlled trial.
Hamuryudan V; Mat C; Saip S; Ozyazgan Y; Siva A; Yurdakul S; Zwingenberger K; Yazici H
Ann Intern Med; 1998 Mar; 128(6):443-50. PubMed ID: 9499327
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of systemic recombinant interferon-alpha in Behçet's disease.
Georgiou S; Monastirli A; Pasmatzi E; Gartaganis S; Goerz G; Tsambaos D
J Intern Med; 1998 May; 243(5):367-72. PubMed ID: 9651559
[TBL] [Abstract][Full Text] [Related]
12. Interferon therapy for Behçet's disease.
Alpsoy E; Yilmaz E; Başaran E
J Am Acad Dermatol; 1994 Oct; 31(4):617-9. PubMed ID: 8089288
[TBL] [Abstract][Full Text] [Related]
13. Results of interferon-alfa therapy in patients with Behçet uveitis.
Tugal-Tutkun I; Güney-Tefekli E; Urgancioglu M
Graefes Arch Clin Exp Ophthalmol; 2006 Dec; 244(12):1692-5. PubMed ID: 16673135
[TBL] [Abstract][Full Text] [Related]
14. Longterm visual prognosis of patients with ocular Adamantiades-Behçet's disease treated with interferon-alpha-2a.
Krause L; Altenburg A; Pleyer U; Köhler AK; Zouboulis CC; Foerster MH
J Rheumatol; 2008 May; 35(5):896-903. PubMed ID: 18412306
[TBL] [Abstract][Full Text] [Related]
15. Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial.
Jacobson IM; Dore GJ; Foster GR; Fried MW; Radu M; Rafalsky VV; Moroz L; Craxi A; Peeters M; Lenz O; Ouwerkerk-Mahadevan S; De La Rosa G; Kalmeijer R; Scott J; Sinha R; Beumont-Mauviel M
Lancet; 2014 Aug; 384(9941):403-13. PubMed ID: 24907225
[TBL] [Abstract][Full Text] [Related]
16. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial.
Escudier B; Pluzanska A; Koralewski P; Ravaud A; Bracarda S; Szczylik C; Chevreau C; Filipek M; Melichar B; Bajetta E; Gorbunova V; Bay JO; Bodrogi I; Jagiello-Gruszfeld A; Moore N;
Lancet; 2007 Dec; 370(9605):2103-11. PubMed ID: 18156031
[TBL] [Abstract][Full Text] [Related]
17. Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial.
Manns M; Marcellin P; Poordad F; de Araujo ES; Buti M; Horsmans Y; Janczewska E; Villamil F; Scott J; Peeters M; Lenz O; Ouwerkerk-Mahadevan S; De La Rosa G; Kalmeijer R; Sinha R; Beumont-Mauviel M
Lancet; 2014 Aug; 384(9941):414-26. PubMed ID: 24907224
[TBL] [Abstract][Full Text] [Related]
18. [Adamantiades-Behçet disease. Therapeutic administration of systemic recombinant interferon-alpha-2a].
Zouboulis CC; Treudler R; Orfanos CE
Hautarzt; 1993 Jul; 44(7):440-5. PubMed ID: 8365878
[TBL] [Abstract][Full Text] [Related]
19. Interferon alfa-2a modifies the course of subfoveal and juxtafoveal choroidal neovascularisation.
Engler C; Sander B; Villumsen J; Lund-Andersen H
Br J Ophthalmol; 1994 Oct; 78(10):749-53. PubMed ID: 7528534
[TBL] [Abstract][Full Text] [Related]
20. Results of interferon alpha-2a therapy in patients with Behcet's disease.
Yalçindağ FN; Uzun A
J Ocul Pharmacol Ther; 2012 Aug; 28(4):439-43. PubMed ID: 22455657
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
